Published in Cardiovascular Week, March 16th, 2009
The trial, with a mean follow-up of 21 months, randomised 4628 patients with atrial fibrillation and at least one other cardiovascular risk factor to either dronedarone or placebo. Results found 24% fewer deaths or hospitalisations (the primary composite endpoint) in the treatment group than in the placebo – a hazard...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.